[Adult primary XXXX . Report of 36 cases].

@entity1 @entity4289 @entity7139 @entity417 @entity882 @entity2590 @entity1334 @entity381 @entity1210
Between 1989 and 1999, 36 cases with primary @entity2590 were diagnosed. They were 15 male and 21 females, the median age was 62 years (range: 22 to 90 years). Eighty one per cent of @entity1 were presented symptoms of @entity417 . Lymphadenopathy, @entity381 and skin manifestations were noted in 25% of cases. Hemogram showed @entity417 , @entity1210 and @entity882 respectively in 97%, 44% and 55% of cases. @entity417 with @entity7139 (AREB) is the most frequent @entity1334 subtypes of @entity4289 (17 cases). Cytogenetic study concerned 24 @entity1 . In 13 cases the karyotype was pathological with deletion 5 q in 64% of cases. Seventeen @entity1 have received a chemotherapy. Survival rate to 36 months is 11%. At the time, the only curative treatment is the bone marrow transplantation, which is proposed to young @entity1 with HLA identical donor.
